Clinical Trial

Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 10, 2025 (before its estimated December 13, 2025 completion). Its status may not reflect the trial's current state.
Summary
Exploratory clinical study of CNCT19 anti CD19 cell therapy in the treatment of refractory autoimmune diseases,To evaluate the safety and tolerability of CNCT19 in patients with refractory systemic lupus erythematosus (lupus nephritis, immune thrombocytopenia), refractory ANCA-associated vasculitis, and refractory dermatomyositis on the basis of standard of care.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-15.
Trial Details
NCT Number NCT06316791
Lead Sponsor Juventas Cell Therapy Ltd.
Conditions Lupus Erythematosus, Systemic
Enrollment 24 participants
Start Date 2021-12-14
Primary Completion 2025-12-13 (estimated)
Study Completion 2025-12-13 (estimated)
Updated on ClinicalTrials.gov 2025-02-10